Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 and Irinotecan: Practical Pharmacogenomics Arrives in Cancer Therapy

4534 Background: Results from the Phase III TARGETs study showed that sorafenib significantly prolonged progression-free survival compared with placebo in patients with advanced renal cell carcinoma. Overall survival was longer with sorafenib than placebo with a hazard ratio of 0.72. The impact of sorafenib treatment on health-related quality of life (HRQL) and symptoms was also evaluated. Methods: HRQL was measured by the Functional Assessment of Cancer Therapy-General (FACT-G). Symptoms were measured by the FACT-Kidney Cancer Symptom Index (FKSI), in which patients used a Likert scale (0–4) to respond to each of 15 items. FACT-G and FKSI were administered at baseline, at Day 1 of each cycle, and at end-of-treatment visit. Statistical analyses used a random coefficient model over five cycles, using MSKCC risk and treatment as factors and baseline score and relative days as covariates, adjusted for multiple comparisons with Bonferroni correction. Results: A total of 903 patients were randomized. The FACT-...